Overview

Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be assessed and correlated with CFA.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott Products
Collaborator:
Datamap
Treatments:
Pancreatin
Pancrelipase